Biotechnology major Biocon today said it has received EU GMP certification for its sterile drug product manufacturing facility in Bengaluru.
The facility was inspected by the European agencies in March 2018, Biocon said in a filing to BSE.
"This facility is used for the manufacture of Biocon's portfolio of biosimilars," a company spokesperson said.
Earlier in May, in a regulatory filing Biocon had said it had received a preliminary report from the European Regulator post inspection of its sterile drug product facility in Bengaluru in March 2018.
"The report lists six major observations with no observation classified as critical. We will submit a corrective and preventive action plan to the European inspection agency within the stipulated time period," a company spokesperson had said.
Shares of Biocon Ltd today closed at Rs 628.15 on BSE, down 0.02 per cent from previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
